Stifel Nicolaus Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $49.00

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective dropped by analysts at Stifel Nicolaus from $53.00 to $49.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 15.33% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank of Canada dropped their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research report on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday. JMP Securities reiterated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday. HC Wainwright reiterated a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research report on Thursday. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $75.00.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock traded down $0.82 during mid-day trading on Thursday, reaching $42.49. The company’s stock had a trading volume of 357,475 shares, compared to its average volume of 1,962,554. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10. The company has a market cap of $3.63 billion, a P/E ratio of -15.03 and a beta of 1.67. The firm’s 50-day moving average is $42.06 and its two-hundred day moving average is $46.25.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. Sell-side analysts anticipate that CRISPR Therapeutics will post -5.08 EPS for the current year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at $10,002,854. This trade represents a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of CRSP. Envestnet Asset Management Inc. raised its holdings in CRISPR Therapeutics by 2.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 56,033 shares of the company’s stock worth $2,205,000 after buying an additional 1,256 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in CRISPR Therapeutics during the 4th quarter worth approximately $285,000. Wells Fargo & Company MN raised its holdings in CRISPR Therapeutics by 8.4% during the 4th quarter. Wells Fargo & Company MN now owns 220,123 shares of the company’s stock worth $8,664,000 after buying an additional 17,094 shares during the period. ExodusPoint Capital Management LP acquired a new stake in CRISPR Therapeutics during the 4th quarter worth approximately $1,883,000. Finally, Pictet Asset Management Holding SA raised its holdings in CRISPR Therapeutics by 9.0% during the 4th quarter. Pictet Asset Management Holding SA now owns 272,704 shares of the company’s stock worth $10,734,000 after buying an additional 22,414 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.